Articles producció científica> Medicina i Cirurgia

Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: A 24-week double-blind, randomized, parallel, placebo-controlled trial

  • Identification data

    Identifier: PC:1539
    Handle: https://hdl.handle.net/20.500.11797/PC1539
    Authors:
    José FrancoJudith UsallElena Huerta-RamosJavier LabadJesús CoboChristian NúñezMarta CreusGemma García ParésDaniel CuadrasEva MiquelJulio César ReyesMercedes Roca
    Abstract:
    The potential therapeutic utility of estrogens in schizophrenia is increasingly being recognized. Raloxifene, a selective estrogen receptor modulator, appears to act similarly to estrogens on dopamine and serotonin brain systems. One previous trial by our team found that raloxifene was useful to improve negative, positive, and general psychopathological symptoms, without having the negative side effects of estrogens. In this study, we assess the utility of raloxifene in treating negative and other psychotic symptoms in postmenopausal women with schizophrenia exhibiting prominent negative symptoms. This was a 24-week, randomized, parallel, double-blind, placebo-controlled study. Patients were recruited from the inpatient and outpatient departments of Parc Sanitari Sant Joan de Déu, Hospital Universitari Institut Pere Mata, and Corporació Sanitària Parc Taulí. Seventy postmenopausal women with schizophrenia (DSM-IV) were randomized to either adjunctive raloxifene (38 women) or adjunctive placebo (32 women). Psychopathological symptoms were assessed at baseline and at weeks 4, 12, and 24 with the Positive and Negative Syndrome Scale (PANSS) and the Scale for the Assessment of Negative Symptoms (SANS). The addition of raloxifene (60 mg/d) to regular antipsychotic treatment significantly reduced negative (P = .027), general (P = .003), and total symptomatology (P = .005) measured with the PANSS during the 24-week trial, as compared to women receiving placebo. Also Alogia SANSS subscale improved more in the raloxifene (P = .048) than the placebo group. In conclusion, raloxifene improved negative and general psychopathological symptoms, compared with antipsychotic medication alone, in postmenopausal women with schizophrenia. These data replicate our previous results with a lar

  • Others:

    Author, as appears in the article.: José Franco; Judith Usall; Elena Huerta-Ramos; Javier Labad; Jesús Cobo; Christian Núñez; Marta Creus; Gemma García Parés; Daniel Cuadras; Eva Miquel; Julio César Reyes; Mercedes Roca
    Department: Medicina i Cirurgia
    URV's Author/s: FRANCO VÁSQUEZ, JOSÉ GABRIEL; Judith Usall; Elena Huerta-Ramos; Javier Labad; Jesús Cobo; Christian Núñez; Marta Creus; Gemma García Parés; Daniel Cuadras; Eva Miquel; Julio César Reyes; Mercedes Roca
    Keywords: SERM negative symptoms estrogen
    Abstract: The potential therapeutic utility of estrogens in schizophrenia is increasingly being recognized. Raloxifene, a selective estrogen receptor modulator, appears to act similarly to estrogens on dopamine and serotonin brain systems. One previous trial by our team found that raloxifene was useful to improve negative, positive, and general psychopathological symptoms, without having the negative side effects of estrogens. In this study, we assess the utility of raloxifene in treating negative and other psychotic symptoms in postmenopausal women with schizophrenia exhibiting prominent negative symptoms. This was a 24-week, randomized, parallel, double-blind, placebo-controlled study. Patients were recruited from the inpatient and outpatient departments of Parc Sanitari Sant Joan de Déu, Hospital Universitari Institut Pere Mata, and Corporació Sanitària Parc Taulí. Seventy postmenopausal women with schizophrenia (DSM-IV) were randomized to either adjunctive raloxifene (38 women) or adjunctive placebo (32 women). Psychopathological symptoms were assessed at baseline and at weeks 4, 12, and 24 with the Positive and Negative Syndrome Scale (PANSS) and the Scale for the Assessment of Negative Symptoms (SANS). The addition of raloxifene (60 mg/d) to regular antipsychotic treatment significantly reduced negative (P = .027), general (P = .003), and total symptomatology (P = .005) measured with the PANSS during the 24-week trial, as compared to women receiving placebo. Also Alogia SANSS subscale improved more in the raloxifene (P = .048) than the placebo group. In conclusion, raloxifene improved negative and general psychopathological symptoms, compared with antipsychotic medication alone, in postmenopausal women with schizophrenia. These data replicate our previous results with a larger sample and a longer follow-up. Trial registration: NCT01573637.
    Research group: Grup d'Investigació en Psiquiatria
    Thematic Areas: Ciències de la salut Ciencias de la salud Health sciences
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 0586-7614
    Author identifier: orcid.org/0000-0001-9255-8084; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D; N/D
    Record's date: 2016-05-19
    Last page: 317
    Journal volume: 42
    Papper version: info:eu-repo/semantics/publishedVersion
    Link to the original source: https://academic.oup.com/schizophreniabulletin/article/42/2/309/2518962
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Article's DOI: 10.1093/schbul/sbv149
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2016
    First page: 309
    Publication Type: Article Artículo Article

  • Keywords:

    Antihormones
    Estrògens
    Esquizofrènia -- Tractament
    SERM
    negative symptoms
    estrogen
    Ciències de la salut
    Ciencias de la salud
    Health sciences
    0586-7614

  • Documents:

    DocumentPrincipal

  • Cerca a google

    Search to google scholar